Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Apr;3(2):87-91.
doi: 10.1016/j.bsheal.2021.02.001. Epub 2021 Feb 10.

An update to monoclonal antibody as therapeutic option against COVID-19

Paroma Deb  1 , Md Maruf Ahmed Molla  2 , K M Saif-Ur-Rahman  3
Affiliations
Review

An update to monoclonal antibody as therapeutic option against COVID-19

Paroma Deb et al. Biosaf Health. 2021 Apr.

Abstract

With the number of Coronavirus Disease 2019 (COVID-19) cases soaring worldwide and limited vaccine availability for the general population in most countries, the monoclonal antibody (mAb) remains a viable therapeutic option to treat COVID-19 disease and its complications, especially in the elderly individuals. More than 50 monoclonal antibody-related clinical trials are being conducted in different countries around the world, with few of them nearing the completion of the third and fourth phase clinical trial. In view of recent emergency use authorization (EUA) from the FDA (Food and Drug Administration) of casirivimab and imdevimab, it is of importance that mAbs, already used to treat diseases such as Ebola and respiratory syncytial virus (RSV) infection, are discussed in scientific communities. This brief review discusses the mechanism of action and updates to clinical trials of different monoclonal antibodies used to treat COVID-19, with special attention paid to SARS-CoV-2 immune response in host cells, target viral structures, and justification of developing mAbs following the approval and administration of potential effective vaccine among vulnerable populations in different countries.

Keywords: Antibody therapy; Coronavirus; Monoclonal antibody; SARS-CoV-2; mAb.

PubMed Disclaimer

References

    1. Tillett R., Sevinsky J., Hartley P., Kerwin H., Crawford N., Gorzalski A. Genomic evidence for reinfection with SARS-CoV-2: a case study. Lancet Infect. Dis. 2020;21(1):52–58. doi: 10.1016/S1473-3099(20)30764-7. - DOI - PMC - PubMed
    1. Pan H., Peto R., Henao-Restrepo A., Preziosi M., Sathiyamoorthy V., Karim Q., Alejandria M. Repurposed antiviral drugs for Covid-19 — interim WHO solidarity trial results. N. Engl. J. Med. 2020;384:497–511. doi: 10.1056/NEJMoa2023184. - DOI - PMC - PubMed
    1. Winkler A., Koepsell S. The use of convalescent plasma to treat emerging infectious diseases. Curr. Opin. Hematol. 2015;22(6):521–526. doi: 10.1097/moh.0000000000000191. - DOI - PubMed
    1. Wang C., Li W., Drabek D., Okba N., van Haperen R., Osterhaus A. A human monoclonal antibody blocking SARS-CoV-2 infection. Nat. Commun. 2020;11(10):2251. doi: 10.1038/s41467-020-16256-y. - DOI - PMC - PubMed
    1. Marovich M., Mascola J., Cohen M. Monoclonal antibodies for prevention and treatment of COVID-19. JAMA. 2020;324(2):131–132. doi: 10.1001/jama.2020.10245. - DOI - PubMed